Home India Ministry of Health and Family Welfare Submission of Post Approval Changes Applications through SUG...
Date: 2021-09-29 Category: Not Applicable State: Union Government Country: India

Submission of Post Approval Changes Applications through SUGAM Portal

Issued by Ministry of Health and Family Welfare · Central Drugs Standard Control Organization

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task

Executive Summary & Key Takeaways

**Summary:** This notice from the Directorate General of Health Services, Central Drugs Standard Control Organisation (CDSCO), BABE Division, announces the mandatory online submission of Post Approval Changes applications via the SUGAM portal (www.cdscoonline.gov.in) for BABE Study Permission and Import Licence for Export purposes. Effective October 8, 2021, the CDSCO will no longer accept offline submissions (hard copy or email) for these applications. All stakeholders are directed to utilize the online portal for submitting Post Approval Changes applications. This notice is addressed to all stakeholders via the CDSCO website, State/UT Licensing Authorities for information and necessary action, and the CDAC Team. The Drugs Controller General of India, Dr. V. G. Somani, issued this notice on September 24, 2021. The reference number for this notice is F. No. 12092021BABEMisc16DC Pt. File.

Key Entities Referenced

Central Drugs Standard Control Organisation: A national regulatory body in India responsible for the regulation of pharmaceuticals and medical devices. BABE Division: A division within the Central Drugs Standard Control Organisation (CDSCO) likely dealing with Bioavailability and Bioequivalence studies. SUGAM Portal: An online portal (www.cdscoonline.gov.in) used for regulatory submissions to the Central Drugs Standard Control Organisation (CDSCO). Post Approval Changes: Refers to changes made to a drug product or process after its initial approval by a regulatory authority. BABE Study Permission: Permission required to conduct Bioavailability and Bioequivalence studies. Import Licence for Export purpose: A license required to import drugs for the purpose of exporting them. Dr. V. G. Somani: The Drugs Controller General of India at the time of the notice. CDSCO Website: The official website of the Central Drugs Standard Control Organisation (CDSCO), used for disseminating information to stakeholders.
Official Source Record View Original Source →
See Full Document Text
F. No. 12-09/2021/BA-BE/Misc-16/DC (Pt. File) Government of India Directorate General of Health Service Central Drugs Standard Control Organisation (BABE Division For Export) FDA Bhawan, Kotla Road, New Delhi, Dated: 24 |4) >} NOTICE Sub: Submission of Post Approval Changes Applications through SUGAM Portal - Reg. In order to streamline the regulatory submission procedure, the submission of applications on Post Approval Changes in BA/BE Study Permission and Import Licence for Export purpose is functional on online system of SUGAM Portal (www.cdscoonline.gov.in). Applicants seeking for approval of such Post Approval Changes may now apply through the online portal. The facility of offline submission of applications in hard copy or through e-mail may not be available after 8" October 2021 for processing. wr \— (Dr. V. G. Somani) Drugs Controller General (India) To, 1. All stakeholders through CDSCO Website 2. State/ UT Licensing Authorities (For information and necessary action) 3. CDAC Team

Continue your research